Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT07854782· Regeneron Pharmaceuticals· Source

• Accurate Point of Care Liver Disease Diagnostics (Phase 2)

  NCT07518784· University of California, San Diego· Source

• ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Boehringer Ingelheim· Source

• Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers

  NCT07172997· Royal College of Surgeons in Ireland - Medical University of Bahrain· Source

• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05809934· AstraZeneca· Source

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Boehringer Ingelheim· Source

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Boehringer Ingelheim· Source

• Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

  NCT06104319· GlaxoSmithKline· Source

• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  NCT03884075· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease

  NCT07285135· Singapore General Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 4
• Gene Expression Profiling 24
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 9
• Metabolomics 18
• Mass Spectrometry 4
• Flow Cytometry 1
• Immunohistochemistry 12
• Magnetic Resonance Imaging 7
• Machine Learning 2
• Cohort Studies 27
• Genome-Wide Association Study 3

• Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study.

  Phytomedicine, Apr 2025

• Exploring the mechanism of berberine treatment for atherosclerosis combined with non-alcoholic fatty liver disease based on bioinformatic and experimental study.

  PLoS One, Dec 2024

See which targets of this disease your abstract mentions, and go to the people working on them.